IOVA – iovance biotherapeutics, inc. (US:NASDAQ)
Stock Stats
News
3/5
05:55 pm
iova
Low
Iovance Biotherapeutics: The High-Risk Cancer Stock I Think Could Change a Portfolio by 2036 [Yahoo! Finance]
3/5
10:24 am
iova
High
Iovance Biotherapeutics (IOVA) had its price target raised by UBS Group AG from $2.00 to $4.00. They now have a "neutral" rating on the stock.
3/3
08:50 am
iova
Low
Iovance Biotherapeutics (IOVA) was upgraded by Citizens Jmp from "market perform" to "market outperform". They now have a $5.00 price target on the stock.
2/27
07:35 pm
iova
Low
Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success [Yahoo! Finance]
2/27
04:21 pm
iova
Low
Is Iovance Biotherapeutics (IOVA) Pricing Reflect Recent Cell Therapy Progress Accurately [Yahoo! Finance]
2/24/2026
07:00 am
iova
23.9%
BEAT
11/6/2025
08:00 am
iova
16.7%
BEAT
8/7/2025
04:01 pm
iova
-20.7%
MISS
3/5
10:03 am
Maintains
Neutral
Neutral
UBS
Medium
9.9%
2/25
10:56 am
Maintains
Overweight
Overweight
Barclays
High
-10.3%
2/25
10:56 am
Maintains
Overweight
Overweight
Barclays
High
-10.3%
12/24
06:15 am
Upgrades
Strong-Buy
Barclays PLC
Low
2.9%
12/17
12:45 pm
Maintains
Overweight
Overweight
Barclays
Low
1.0%
3/4
05:02 pm
iova
Medium
Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 02 Filed by: Vogt Frederick G
3/4
05:01 pm
iova
Medium
Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 02 Filed by: BILINSKY IGOR
3/4
05:01 pm
iova
Medium
Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 02 Filed by: Puri Raj K.
3/4
05:00 pm
iova
Medium
Form 4 IOVANCE BIOTHERAPEUTICS, For: Mar 02 Filed by: GRAF FINCKENSTEIN FRIEDRICH
2/26
05:00 pm
iova
Medium
Form 4 IOVANCE BIOTHERAPEUTICS, For: Feb 24 Filed by: Kirby Daniel Gordon
Show more
Top News Gainers
5/15 Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs 36.1%
2/24 Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: Avoro Capital Advisors LLC 27.4%
4/13 Iovance Biotherapeutics Announces H. Lee Moffitt Cancer Center to Present Lung Cancer Clinical Data at American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 17.5%
11/7 Iovance Biotherapeutics to Present at Upcoming Investor Conferences in November 15.8%
3/23 Novan up 27% on favorable safety profile of SB206, Covid-19 plan [Seeking Alpha] 11.6%
2/25 Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.3%
1/8 Iovance Biotherapeutics Inc (NASDAQ: IOVA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.4%
6/3 Iovance Biotherapeutics Inc (NASDAQ: IOVA) had its price target raised by analysts at HC Wainwright from $26.00 to $32.00. They now have a "buy" rating on the stock. 8.0%
10/2 Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting 6.9%
11/4 Q3/2019 9/30/2019 EPS -0.400 ZacksConsensus -0.400 ActVsEst 0.000 - In-Line 6.6%
Top News Decliners
3/16 Iovance Biotherapeutics Inc (NASDAQ: IOVA) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -20.2%
1/12 BRIEF-Iovance Biotherapeutics Obtains License To Develop And Commercialize A Novel IL-2 Analog [Reuters] -14.5%
5/31 Iovance Biotherapeutics Inc (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $30.00 price target on the stock. -10.9%
4/28 Frazier Healthcare Partners Adds Experienced Capital Markets Executive to Life Sciences Team -10.0%
9/25 Form EFFECT IOVANCE BIOTHERAPEUTICS, -8.1%
8/1 Form 8-K IOVANCE BIOTHERAPEUTICS, For: Aug 01 -6.9%
6/11 Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors -5.3%
8/2 Iovance Biotherapeutics, Inc. (IOVA) Q2 2019 Earnings Call Transcript [The Motley Fool] -5.1%
4/27 Iovance Biotherapeutics Inc (NASDAQ: IOVA) had its price target raised by analysts at Chardan Capital from $36.00 to $44.00. They now have a "buy" rating on the stock. -4.5%
11/21 Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy -4.4%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3